Département d'Hématologie, Institut de Cancérologie Gustave Roussy, 114 Rue Edouard Vaillant, 94810, Villejuif, France.
DITEP, Institut de Cancérologie Gustave Roussy, Villejuif, France.
Curr Oncol Rep. 2020 Mar 6;22(4):33. doi: 10.1007/s11912-020-0898-8.
Burkitt's lymphoma and its leukemic form (Burkitt cell acute lymphoblastic leukemia) are a highly aggressive disease. We review the classification, clinical presentation, histology, cytogenetics, and the treatment of the disease.
Burkitt's lymphoma might be associated with tumor lysis syndrome which is a potentially fatal complication that occurs spontaneously or upon initiation of chemotherapy. Major improvements were made in the treatment of pediatric and adults population using short-course dose-intensive chemotherapy regimens, usually 1 week after a prephase induction. Addition of Rituximab to chemotherapy has become a standard of care. Relapsed/refractory disease has a very poor prognosis and the benefit from autologous/allogeneic hematopoietic stem cell transplant remains uncertain. Rituximab-based short-course dose-intensive chemotherapy is the standard of care of Burkitt's lymphoma even in the immunodeficiency-related form.
伯基特淋巴瘤及其白血病形式（伯基特细胞急性淋巴细胞白血病）是一种高度侵袭性疾病。我们综述了该病的分类、临床表现、组织病理学、细胞遗传学以及治疗方法。
伯基特淋巴瘤可能与肿瘤溶解综合征相关，这是一种潜在的致命并发症，可自发发生或在化疗开始时发生。通过使用短疗程、剂量密集的化疗方案，儿童和成人的治疗取得了重大进展，通常在预激诱导后 1 周进行。在化疗中加入利妥昔单抗已成为一种标准治疗方法。复发/难治性疾病预后极差，自体/同种异体造血干细胞移植的获益仍不确定。基于利妥昔单抗的短疗程、剂量密集化疗是伯基特淋巴瘤的标准治疗方法，即使是在与免疫缺陷相关的形式中也是如此。
